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Objectives 
The American Society of Clinical 
Oncology recommends that full weight-
based doses of chemotherapy be used 
to treat obese patients with cancer. 
However, many oncologists limit the 
dose of chemotherapy based on ideal 
body weight or a maximum body surface 
area (BSA) of m2. The objective of our 
study is to determine how weight-based 
chemotherapy dosing affects toxicity, 
treatment delays, and laboratory values 
in a cohort of obese gynecologic cancer 
patients at our institution. We 
hypothesize that full weight-based 
dosing in obese patients does not 
increase adverse chemotherapy 
outcomes. 
 
Methods 
  We performed a retrospective review 
of patients at our institution with a BSA ≥ 
m2 who received weight-based 
chemotherapy dosing for a gynecologic 
malignancy beginning in January 2013 
(n=27). These subjects were matched 
with control patients (n=27) with BSA < 
m2 who had similar co-morbidities and 
prior cancer treatment. Data regarding 
the patients’ demographic 
characteristics, prior chemotherapy, 
laboratory values, and symptoms noted 
at the time of clinic visit, and medical co-
morbidities were collected. Lab values 
were evaluated through two cycles of 
chemotherapy in order to evaluate 
toxicities. Chemotherapy agents 
analyzed were those dosed according to 
BSA, including paclitaxel, gemcitabine, 
and liposomal doxorubicin. 
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Demographic and clinical information 
was compared between the two groups 
using Fisher’s exact test for categorical 
variables and the Wilcoxon two sample 
test for continuous variables.  
Results 
The two groups were similar in age and 
co-morbidities, but significantly different 
in terms of BSA, weight, and BMI. In the 
obese (BSA ≥ m2) group, 3.7% of 
patients received a dose of 
chemotherapy 30% higher than they 
would have received with a BSA cap of 
m2, while 18.5% of patients received a 
15% higher dose, and 44.4% of patients 
received a 10% higher dose. When 
comparing pre- and post-treatment 
laboratory values between obese and 
non-obese patients, there were no 
differences in overall WBC, ANC, 
platelets or creatinine (p>0.3). There 
was also no difference between the 
obese and non-obese groups with 
regards to treatment delays (p=NS), 
transfusions (p=NS), symptoms noted at 
follow up visit (p=NS) and hospital 
admissions (p=NS).  
 
 
Conclusions 
At our institution, gynecologic cancer 
patients treated with full-dose 
chemotherapy using actual BSA had no 
increase in toxicities, treatment delays 
or excessive laboratory abnormalities 
when compared to patients with BSA < 
m2.  We plan to increase our cohort to 
ensure these observations are valid. 
Based on our initial analysis, 
consideration should be given to using 
weight-based dosing in obese patients 
receiving chemotherapy for gynecologic 
malignancies.  Further investigation is 
required to determine whether weight-
based chemotherapy dosing leads to 
increased overall survival and 
progression-free survival in obese 
gynecologic cancer patients.  
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